Literature DB >> 17619833

Acute pulmonary embolism: risk stratification in the emergency department.

C Becattini1, G Agnelli.   

Abstract

Pulmonary embolism is a common disease associated with a high mortality rate. Death due to pulmonary embolism occurs more commonly in undiagnosed patients before hospital admission or during the initial in-hospital stay. Thus, mortality could be reduced by prompt diagnosis, early prognostic stratification and more intensive treatment in patients with adverse prognosis. Mortality is particularly high in patients with pulmonary embolism presenting with arterial hypotension or cardiogenic shock. In patients with pulmonary embolism and normal blood pressure, a number of clinical features and objective findings have been associated with a high risk of adverse in-hospital outcome. Advanced age and concomitant cardiopulmonary disease are clinical risk factors for in-hospital mortality. The Bburden of thromboembolism, as assessed by lung scan or spiral CT, and right ventricle overload, as assessed by echocardiography and probably spiral CT, have been claimed to be risk factors for in-hospital mortality. Elevated serum levels of troponins have been shown to be associated with right ventricular overload and adverse in-hospital outcomes in patients with pulmonary embolism. Despite the currently available evidence, no definite prognostic value can be assigned to any of the individual risk factors or cluster of them. Large prospective trials should be carried out to validate individual risk factors or clusters of risk factors able to identify patients with acute pulmonary embolism at high risk for in-hospital mortality. These patients could afford the trade-off of an increased risk of side effects related to a more aggressive treatment, such as thrombolysis or surgical or interventional procedures.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17619833     DOI: 10.1007/s11739-007-0033-y

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


  65 in total

1.  Cardiac troponin elevations in patients without acute coronary syndrome.

Authors:  Christian W Hamm; Evangelos Giannitsis; Hugo A Katus
Journal:  Circulation       Date:  2002-12-03       Impact factor: 29.690

Review 2.  D-dimer testing: advantages and limitations in emergency medicine for managing acute venous thromboembolism.

Authors:  Sergio Siragusa
Journal:  Intern Emerg Med       Date:  2006       Impact factor: 3.397

3.  Prognostic significance of inverted T waves in patients with acute pulmonary embolism.

Authors:  Masami Kosuge; Kazuo Kimura; Toshiyuki Ishikawa; Toshiaki Ebina; Kiyoshi Hibi; Kengo Tsukahara; Masahiko Kanna; Noriaki Iwahashi; Jyun Okuda; Naoki Nozawa; Hiroyuki Ozaki; Hideto Yano; Tatuya Nakati; Ikuyoshi Kusama; Satoshi Umemura
Journal:  Circ J       Date:  2006-06       Impact factor: 2.993

4.  Prognostic value of the ECG on admission in patients with acute major pulmonary embolism.

Authors:  A Geibel; M Zehender; W Kasper; M Olschewski; C Klima; S V Konstantinides
Journal:  Eur Respir J       Date:  2005-05       Impact factor: 16.671

5.  Appearance of right bundle branch block in electrocardiograms of patients with pulmonary embolism as a marker for obstruction of the main pulmonary trunk.

Authors:  D B Petrov
Journal:  J Electrocardiol       Date:  2001-07       Impact factor: 1.438

6.  Plasma heart-type fatty acid binding protein is superior to troponin and myoglobin for rapid risk stratification in acute pulmonary embolism.

Authors:  Anna Kaczyñska; Maurice M A L Pelsers; Anna Bochowicz; Maciej Kostrubiec; Jan F C Glatz; Piotr Pruszczyk
Journal:  Clin Chim Acta       Date:  2006-05-15       Impact factor: 3.786

7.  Brain natriuretic peptide in hemodynamically stable acute pulmonary embolism.

Authors:  M Söhne; M Ten Wolde; F Boomsma; J B Reitsma; J D Douketis; H R Büller
Journal:  J Thromb Haemost       Date:  2005-12-23       Impact factor: 5.824

8.  Biomarker-based risk assessment model in acute pulmonary embolism.

Authors:  Maciej Kostrubiec; Piotr Pruszczyk; Anna Bochowicz; Ryszard Pacho; Marcin Szulc; Anna Kaczynska; Grzegorz Styczynski; Agnieszka Kuch-Wocial; Piotr Abramczyk; Zbigniew Bartoszewicz; Hanna Berent; Krystyna Kuczynska
Journal:  Eur Heart J       Date:  2005-05-23       Impact factor: 29.983

9.  ECG score predicts those with the greatest percentage of perfusion defects due to acute pulmonary thromboembolic disease.

Authors:  Stephen Iles; Campbell J Le Heron; Gwyn Davies; John G Turner; Lutz E L Beckert
Journal:  Chest       Date:  2004-05       Impact factor: 9.410

10.  Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism.

Authors:  H R Büller; B L Davidson; H Decousus; A Gallus; M Gent; F Piovella; M H Prins; G Raskob; A E M van den Berg-Segers; R Cariou; O Leeuwenkamp; A W A Lensing
Journal:  N Engl J Med       Date:  2003-10-30       Impact factor: 91.245

View more
  10 in total

Review 1.  Short- and Long-term Mortality Risk After Acute Pulmonary Embolism.

Authors:  Rajesh Gupta; Dylan D Fortman; Daniel R Morgenstern; Christopher J Cooper
Journal:  Curr Cardiol Rep       Date:  2018-10-11       Impact factor: 2.931

2.  The role of ST-segment elevation in lead aVR in the risk assessment of patients with acute pulmonary embolism.

Authors:  Karin Janata; Thomas Höchtl; Catharina Wenzel; Rudolf Jarai; Barbara Fellner; Alexander Geppert; Peter Smetana; Vera Havranek; Kurt Huber
Journal:  Clin Res Cardiol       Date:  2011-12-22       Impact factor: 5.460

3.  Mortality at 30 and 90 days in elderly patients with pulmonary embolism: a retrospective cohort study.

Authors:  Hernan Polo Friz; Mauro Molteni; Davide Del Sorbo; Lorenzo Pasciuti; Matteo Crippa; Giulia Villa; Dario Francesco Meloni; Laura Primitz; Andrea Galli; Magda Rognoni; Luca Cavalieri d'Oro; Guido Arpaia; Claudio Cimminiello
Journal:  Intern Emerg Med       Date:  2014-12-25       Impact factor: 3.397

4.  Early anticoagulation is associated with reduced mortality for acute pulmonary embolism.

Authors:  Sean B Smith; Jeffrey B Geske; Jennifer M Maguire; Nicholas A Zane; Rickey E Carter; Timothy I Morgenthaler
Journal:  Chest       Date:  2010-01-15       Impact factor: 9.410

5.  In-hospital mortality for pulmonary embolism: relationship with chronic kidney disease and end-stage renal disease. The hospital admission and discharge database of the Emilia Romagna region of Italy.

Authors:  Fabio Fabbian; Massimo Gallerani; Marco Pala; Alfredo De Giorgi; Raffaella Salmi; Fabio Manfredini; Francesco Portaluppi; Francesco Dentali; Walter Ageno; Dimitri P Mikhailidis; Roberto Manfredini
Journal:  Intern Emerg Med       Date:  2012-12-18       Impact factor: 3.397

6.  The Risk-based Treatment of Acute Pulmonary Embolism.

Authors:  Luca Masotti; Annalisa Mannucci; Fabio Antonelli; Vincenzo Maurini; Roberto Testa; Sergio Marchetti; Giancarlo Landini; Roberto Cappelli
Journal:  J Clin Med Res       Date:  2009-03-31

Review 7.  Prognostic stratification of acute pulmonary embolism: focus on clinical aspects, imaging, and biomarkers.

Authors:  Luca Masotti; Marc Righini; Nicolas Vuilleumier; Fabio Antonelli; Giancarlo Landini; Roberto Cappelli; Patrick Ray
Journal:  Vasc Health Risk Manag       Date:  2009-07-14

8.  Cardiothoracic CT: one-stop-shop procedure? Impact on the management of acute pulmonary embolism.

Authors:  Pauline J Abrahams-van Doorn; Ieneke J C Hartmann
Journal:  Insights Imaging       Date:  2011-08-06

Review 9.  Pulmonary embolism in the elderly: a review on clinical, instrumental and laboratory presentation.

Authors:  Luca Masotti; Patrick Ray; Marc Righini; Gregoire Le Gal; Fabio Antonelli; Giancarlo Landini; Roberto Cappelli; Domenico Prisco; Paola Rottoli
Journal:  Vasc Health Risk Manag       Date:  2008

10.  Prognostic value of lactates in relation to gas analysis and acid-base status in patients with pulmonary embolism.

Authors:  Kristina Galić; Danijel Pravdić; Zrinko Prskalo; Suzana Kukulj; Boris Starčević; Mladenka Vukojević
Journal:  Croat Med J       Date:  2018-08-31       Impact factor: 1.351

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.